Daniel Mikol
Company: Global Neuroscience Development Amgen
Job title: Executive Medical Director
Bio:
Neuroscience Development lead: early/late stage migraine, pipeline products. Development lead for Erenumab (Aimovig) for migraine prevention.
Seminars:
Keynote: Migraine; From Hysteria to Neurobiological Entity 8:40 am
Understand pathophysiology data from imaging studies Summarize new guidelines on developing Acute Treatment for Migraine Assess treatment gaps in Preventive treatment of Migraine and the unmet patient needRead more
day: Day One
Workshop A 9:00 am - 10:00 am
Working with Migraine Patient Advocacy Organizations on Clinical Trial Design and Recruitment The patient advocacy perspective is one that is commonly discussed amongst migraine stakeholders, getting the insight from those who work to ensure the migraine awareness is widespread and the outreach to patients is great.Read more
Discussing the Current Anti-CGRP Status & the Challenges & Opportunities They Pose 12:00 am - 2:00 pm
day: Day Two
Discussing the Current Anti-CGRP Status & the Challenges & Opportunities They Pose 9:00 am
Understand pathophysiology data from imaging studies Summarize new guidelines on developing Acute Treatment for Migraine Assess treatment gaps in Preventive treatment of Migraine and the unmet patient needRead more
day: Day One
Discussing the Current Anti-CGRP Status & the Challenges & Opportunities They Pose 9:00 am
Understand pathophysiology data from imaging studies Summarize new guidelines on developing Acute Treatment for Migraine Assess treatment gaps in Preventive treatment of Migraine and the unmet patient needRead more
day: Day One